Aarti Pharmalabs reported robust Q2 FY27 results, with revenue jumping 45.9% to Rs 610.5 crore and PAT surging 248.8% to Rs 71.5 crore. The company announced a Rs 149 crore investment for a new Atali Block 2 facility and set a 15-18% revenue and EBITDA CAGR target for the next 3-4 years.
Aarti Pharmalabs Reports Strong Q2 FY27 Growth
Aarti Pharmalabs posted Q2 FY27 revenue of Rs 610.5 crore and a PAT of Rs 71.5 crore.
Reader Takeaway: Exceptional bottom-line growth and clear long-term guidance, though rising raw material costs remain a key monitoring point.
What just happened
Aarti Pharmalabs announced strong financial results for the quarter ended September 2026. Revenue grew 45.9% year-on-year to Rs 610.5 crore, while EBITDA surged 80.2% to Rs 134.6 crore. The company’s PAT saw a substantial 248.8% increase, rising to Rs 71.5 crore compared to Rs 20.5 crore in the same period last year. Diluted EPS for the quarter reached Rs 7.87.
Why this matters
The performance indicates effective capacity utilization from the recently operationalized Tarapur-4 steroid block and Atali Block 1. The company is successfully passing on elevated raw material costs caused by geopolitical pressures to its customers, helping protect margins. The commitment to a 15-18% revenue and EBITDA CAGR over the next four years provides investors with a clear roadmap for medium-term growth expectations.
Capex and Growth Strategy
Aarti Pharmalabs is maintaining an aggressive growth stance, launching a Rs 149 crore brownfield project at Unit 7, Gujarat. The 'Atali Block 2' facility will add 405 KL of capacity dedicated to CDMO/CMO operations, with commercialization slated for H2FY28. Additionally, the firm is directing R&D investments toward TIDES (Peptides & Oligonucleotides) to broaden its specialized portfolio.
Risks to watch
While growth is strong, the company continues to navigate the impact of geopolitical tensions on raw material costs. Investors should monitor how effectively the company sustains margin improvements if these cost pressures intensify or if supply chains face further disruptions.
What to track next
Market participants should watch for progress on the Atali Block 2 construction and future updates regarding the TIDES R&D program. Management reiterated that FY27 capex will remain consistent with the prior year's spend of approximately Rs 400 crore.